TREATMENT OF
MULTIPLE SCLEROSIS
CPT.one Biotech is a biotech company focusing on treatments for Multiple Sclerosis.
About us
What we do
CPT.one Biotech is a Danish biotech company, dedicated to the development of novel treatments primarily for patients suffering from secondary progressive multiple sclerosis (SP-MS).
CPT.one biotech

Technology

Our drug development is based on early development by Medigene, a German biotech company within diabetes, cardiological and autoimmune diseases.

CPT.one Biotech has a strong IP position which includes in-licensed IP from Medigene AG, pending patent applications, and issued patents on the use of CPT-001 to treat multiple sclerosis.

Learn More
About

About CPT.one Biotech

CPT.one Biotech is a Danish privately funded biotech company, dedicated to the development of novel treatments for patients suffering from multiple sclerosis (MS). We are primarily focusing on secondary progressive multiple sclerosis (SP-MS).

Learn More

Publications

CMSC Digging deeper into MS pathology
May 25, 2017

Experimental autoimmune encephalomyelitis (EAE) models of MS were established to test the efficacy of the CPT1 blocker, Etomoxir. Western Blotting was executed in order to test antibody response against brain proteins in EAE animal sera. Antigens recognized by autoantibodies were immunoprecipitated and analyzed by mass spectrometry with the purpose to identify these antigens, and thereby identifying a correlation between MS and brain antigens.

Read more
Blocking of CPT1 reduces stress-induced depression
April 10, 2017

Major depressive disorder is a complex and common mental disease, for which the pathology has not been elucidated. The purpose of this study is to provide knowledge about the importance of mitochondrial dysfunction, dysregulated lipid metabolism and inflammation.

Read more
The role of CPT1 in MS treatment
November 16, 2019

Multiple sclerosis (MS) is an inflammatory autoimmune disease in the central nervous system (CNS) characterized by demyelination, inflammatory plaques, oxidative stress and degradation of the blood-brain barrier (BBB)1,2. The etiology of MS is still not fully understood; however, different hypotheses involving infiltration of peripheral T cells activated by molecular mimicry or bystander activation, which triggers the immune system, have been proposed3.

Read more
What we do
CPT.one Biotech is a Danish biotech company, dedicated to the development of novel treatments primarily for patients suffering from secondary progressive multiple sclerosis (SP-MS).

News

Industriveteran skal foretage gearskifte i biotekselskab med fokus på sklerose

Biotekfirmaet Cpt.one skifter gear og skruer op for ambitionsniveauet med ansættelsen af en erfaren industriveteran med fortid hos blandt andre Pfizer, Leo Pharma og Sanofi som ny topchef.

Read more